What one share of Gossamer Bio holds
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH
Gossamer Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.21 |
|---|---|
| Profit | −$0.48 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.63 |
| Cash and investments | $0.12 |
| Book value | −$0.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.74 | — | — | — | −$0.75 |
| 2018 | — | −$22.59 | $0.54 | −$8.38 | — | −$14.91 |
| 2019 | — | −$3.29 | $0.05 | −$2.70 | — | $5.72 |
| 2020 | — | −$3.55 | $0.02 | −$2.60 | — | $4.34 |
| 2021 | — | −$3.13 | $0.02 | −$2.54 | — | $1.60 |
| 2022 | $0.00 | −$2.71 | $0.00 | −$2.22 | — | $0.13 |
| 2023 | $0.00 | −$1.18 | $0.00 | −$1.04 | — | $0.28 |
| 2024 | $0.51 | −$0.25 | $0.00 | −$0.02 | — | $0.13 |
| 2025 | $0.21 | −$0.75 | $0.00 | −$0.75 | — | −$0.53 |
Common questions about Gossamer Bio
How much does one share of Gossamer Bio earn?
Over the last 12 months, Gossamer Bio lost $0.48 for each share on $0.21 of sales.
Does Gossamer Bio pay a dividend?
Gossamer Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Gossamer Bio’s book value per share?
Gossamer Bio’s book value is negative (−$0.19 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Gossamer Bio have?
Each share of Gossamer Bio has $0.12 of cash and investments, as of June 30, 2026.
What is Gossamer Bio’s free cash flow per share?
−$0.63 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Gossamer Bio bought back shares?
Gossamer Bio’s share count rose about 2395% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.